IceCure Medical Ltd (ICCM)
| Market Cap | 62.79M |
| Revenue (ttm) | 3.29M |
| Net Income (ttm) | -15.32M |
| Shares Out | 56.57M |
| EPS (ttm) | -0.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 221,190 |
| Open | 1.090 |
| Previous Close | 1.105 |
| Day's Range | 1.060 - 1.150 |
| 52-Week Range | 0.480 - 1.660 |
| Beta | 2.42 |
| Analysts | Strong Buy |
| Price Target | 2.50 (+125.23%) |
| Earnings Date | Mar 27, 2025 |
About ICCM
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system ... [Read more]
Financial Performance
In 2024, IceCure Medical's revenue was $3.29 million, an increase of 1.92% compared to the previous year's $3.23 million. Losses were -$15.32 million, 4.55% more than in 2023.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ICCM stock is "Strong Buy" and the 12-month stock price forecast is $2.5.
News
IceCure Medical Ltd (ICCM) Q4 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Conference Call March 27, 2025 10:00 AM ET Company Participants Michael Polyviou - Investor Relations Eyal Shamir - Chief Executive Officer and Dire...
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Expecting FDA decision on marketing authorization for early-stage low risk breast cancer with endocrine therapy Positive ProSense® results were reported through 33 peer-reviewed journals and medical c...
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Interim Data confirm ProSense® cryoablation is highly effective for kidney tumors ≤3 cm and a safe procedure for kidney tumors ≤5 cm in people ineligible for surgery CAESAREA, Israel , March 24, 20...
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
CAESAREA, Israel , March 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that dest...
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
IceCure working in close collaboration with FDA towards De Novo decision CAESAREA, Israel , March 20, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Com...
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference
IceCure exhibited at the prestigious event in Vienna, Austria attended by oncologists, breast surgeons An abstract on ICE3 study results by Dr. Richard Fine was accepted and included in the poster pre...
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
This latest IP win rounds out protection for the cryogenic pump in major global market following grants for the same patent in the U.S., Europe and Japan CAESAREA, Israel , March 17, 2025 /PRNewswire/...
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
Independent study published in Gland Surgery and conducted at Kameda Medical Center in Japan by ProSense® users including Dr. Kizuki Matsumoto and Dr. Eisuke Fukuma Patients who underwent cryoablation...
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel
Application covering a wide range of indications is in line with trends in de-escalation of surgery and growth in minimally invasive cryoablation procedures, pointing to strong potential for increasin...
IceCure's ProSense® in the Spotlight at Society of Interventional Oncology (SIO) Annual Meeting: Award Winning Abstract and Hands-On Training for Breast Cryoablation as Medical Community Anticipates FDA's Market Authorization Decision
Two independent studies of ProSense® cryoablation in breast cancer were presented, one of which won the Highest Scoring Abstract Award in its category Hands-on ProSense® training featured during the S...
IceCure Files for Regulatory Approval of ProSense® Cryoablation System in China
Seeks to expand regulatory approval in China where IceSense3 has already been approved CAESAREA, Israel , Jan. 27, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical...
IceCure Medical CEO Issues Letter to Shareholders & Reports Increase of 42% in ProSense® Sales for 2024 in North America
Increase in sales of ProSense®, based on preliminary unaudited results, demonstrate growing adoption of ProSense® cryoablation for breast tumors. FDA decision on market authorization of ProSense® for ...
IceCure Medical Regains Full Nasdaq Compliance with Nasdaq Minimum Closing Bid Price Rule
CAESAREA, Israel , Jan. 6, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destro...
European Patent Office Issues Intention to Grant Notice to IceCure for its Next-Generation Cryoablation Technology
XSense™ system's innovative cryogenic connector technology designed to improve safety and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Jan. 3, 2025 /PRNewswi...
Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting
ICE3 trial results presented by ICE3 Co-Principal Investigator Dr. Kenneth Tomkovich FDA Advisory Panel voted in favor of IceCure's ProSense® cryoablation benefit-risk profile in early-stage low risk ...
IceCure Medical Ltd (ICCM) Q3 2024 Earnings Call Transcript
IceCure Medical Ltd (NASDAQ:ICCM) Q3 2024 Earnings Conference Call November 26, 2024 10:00 AM ET Company Participants Michael Polyviou - IR Ronen Tsimerman - CFO and Chief Operating Officer Tlalit Te...
IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation
FDA Marketing Authorization Decision on Early Stage-Low Risk Breast Cancer Expected in Q1 2025 Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , Nov. 26, 2024 /PRNewswire/ -...
IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office
Invention facilitates treatment of larger tumors and is a significant leap forward in the field of cryoablation CAESAREA, Israel , Nov. 25, 2024 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("I...
IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024
CAESAREA, Israel , Nov. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing...
IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health
PRECICE study, financed by the Umberto Veronesi Foundation and the Italian Ministry of Health, is led by multidisciplinary collaborators including breast surgeons, interventional radiologists, and bre...
FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer
FDA decision on marketing authorization expected in the first quarter of 2025 CAESAREA, Israel , Nov. 8, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "...
Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders
Comments from key stakeholders, including doctors, nurses, researchers, and breast cancer patients, are available on FDA website FDA Advisory Panel providing recommendations and vote on information co...
IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System
Innovative cryogenic system connector technology designed to improve usability and maintain the integrity of cryogen used in the cryoablation procedure CAESAREA, Israel , Oct. 21, 2024 /PRNewswire/ --...
IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference
ICE3 trial results presentation by Co-Principal Investigator Dr. Kenneth Tomkovich wins EUSOBI 2024 Abstract Award THERMAC Trial on Treatment of Breast Cancer with Percutaneous Thermal Ablation (cryo...
IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate
Publication comes ahead of the FDA Advisory Panel Meeting for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer scheduled for November 7, 2024 96.3% recurrence free rate for w...